Drug Topics

JUNE 9, 2023

Welcome back to RPHCast! This week, our hosts dive into the profitability of A1C testing, and how quick and easy these tests can help maximize your pharmacy's capabilities.

247

247

PharmaVoice

JUNE 9, 2023

The CEO of Sunstone Therapies said the results of a recent trial testing psilocybin in cancer patients with depression were “remarkable.

246

246

Drug Topics

JUNE 9, 2023

Stock solutions to common summer maladies in the pharmacy's front end.

247

247

Pharmacy Times

JUNE 9, 2023

The study will assess the use of the drug to treat impaired social motivation, or asociality, which is a difficult-to-treat symptom of schizophrenia that can cause significant functional impairment.

FDA 182

FDA 182

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Drug Topics

JUNE 9, 2023

Advisers with the FDA endorse a monoclonal antibody treatment for RSV in children, AstraZeneca and Quell sign a $2 billion agreement, and HSS hopes to strengthen the pediatric workforce.

FDA 247

FDA 247

Fierce Healthcare

JUNE 9, 2023

Emerging Alzheimer’s disease medications come with high price tags, but researchers with the University of Chicago calculate that in the long run, it’s much less costly to cover these therapies for | Emerging Alzheimer’s medications come with high price tags, but researchers with the University of Chicago calculate that in the long run, it’s much less costly to cover these therapies for Medicare beneficiaries.

145

145

STAT

JUNE 9, 2023

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress. The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s

FDA 144

FDA Hospitals 144

Drug Topics

JUNE 9, 2023

Cytokine signaling pathways in sera from underrepresented minority patients were found to be enriched.

Immunization 247

Immunization 247

Fierce Healthcare

JUNE 9, 2023

The Federal Trade Commission is building out its deep dive into the pharmacy benefit management industry yet again. | The Federal Trade Commission is building out its deep dive into the pharmacy benefit management industry yet again.

139

139

Drug Topics

JUNE 9, 2023

Nivolumab plus relatlimab showed a clear benefit in progression-free survival, overall survival and objective response rate.

247

247

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

JUNE 9, 2023

Heart monitoring company iRhythm is in hot water with the Food and Drug Administration, which issued a stern warning letter to the device maker this week for marketing its product for “high risk” patients and changing its algorithm without seeking the FDA’s permission. The letter highlights FDA’s growing scrutiny of digital health and patient monitoring tools — as well as the grave impacts even small device glitches can have on patients.

FDA 137

FDA 137

Drug Topics

JUNE 9, 2023

More research is required to make conclusions regarding long-term use and efficacy.

247

247

Fierce Pharma

JUNE 9, 2023

After a daylong discussion among experts on an FDA advisory committee, Eisai and Biogen's Leqembi is heading into the final stretch of its regulatory review on strong footing. | After a daylong discussion among experts on an FDA advisory committee, Eisai and Biogen's Leqembi is heading into the final stretch of its regulatory review on strong footing.

FDA 133

FDA 133

Pharmacy Times

JUNE 9, 2023

Clinical trial recruitment in areas such as Alabama have had difficulty with recruiting non-White patients, and at the heart of the problem is a lack of trust.

Community Pharmacies 130

Community Pharmacies 130

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

JUNE 9, 2023

The scientific paper inspired international headlines with its bold claim that the combination of brain scans and machine learning algorithms could identify people at risk for suicide with 91% accuracy. The promise of the work garnered lead author Marcel Adam Just of Carnegie Mellon University in Pittsburgh and co-author David Brent of the University of Pittsburgh a five-year, $3.8 million grant from the National Institute of Mental Health to conduct a larger follow-up study.

125

125

Pharmacy Times

JUNE 9, 2023

Study highlights the importance of interprofessional decision-making between pharmacists and emergency department medical officers.

123

123

Fierce Healthcare

JUNE 9, 2023

Walgreens Boots Alliance sold its remaining stake in post-acute care and infusion services company Option Care Health for $330 million. | Walgreens Boots Alliance sold its remaining stake in post-acute care and infusion services company Option Care Health for $330 million.

122

122

Pharmacy Times

JUNE 9, 2023

April Gill, chief commercial officer at Tabula Rasa HealthCare, discusses how to identify underserved patients and address social determinants of health.

123

123

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

JUNE 9, 2023

In 2017, the Massachusetts state Legislature passed a law to ensure ease of access to birth control. It says there should be no copay for hormonal birth control prescriptions. It also allows women to fill a 12-month prescription at once. Infertility care has similar protections. The state mandates that plans cover “ medically necessary expenses of diagnosis and treatment of infertility ” if the insurance provides other pregnancy-related benefits.

Insurance 118

Insurance 118

Pharmacy Times

JUNE 9, 2023

There are 8 million cancer survivors who may have limitations in their daily functional ability.

123

123

STAT

JUNE 9, 2023

FRANKFURT — Updated results released Friday highlighted the lasting benefits of a CRISPR-based medicine for blood disorders developed by Vertex Pharmaceuticals and CRISPR Therapeutics, as the treatment awaits regulatory decisions in the United States and Europe.   The treatment, a one-time infusion known as exa-cel, uses CRISPR to fix the genetic faults at the root of sickle cell disease and beta thalassemia.

116

116

Pharmacy Times

JUNE 9, 2023

The CDC has recommended a follow-up nucleic acid amplification test to be used for patients clinically suspected to have influenza, despite a negative POC test.

123

123

Fierce Healthcare

JUNE 9, 2023

The Department of Health and Human Services (HHS) has released a 43-drug list of the Medicare Part B prescription treatments that must repay the program for raising prices above the rate of inflati | The non-final list of 43 prescription drugs and biological products could save Medicare beneficiaries anywhere from $1 to $449 per average dose in out-of-pocket costs from July 1 to Sept. 30.

116

116

STAT

JUNE 9, 2023

WASHINGTON — After getting burned by the high-profile implosion of a digital health company, a senior official at Oklahoma’s Medicaid program said the state would be hesitant to buy into similar products again. “I don’t want to say we’re not receptive,” Terry Cothran, the senior pharmacy director at Oklahoma Health Care Authority said at the Digital Therapeutics Alliance’s summit this week.

Hospitals 114

Hospitals 114

Pharmaceutical Technology

JUNE 9, 2023

WestVac Biopharma has announced that the Chinese authorities have granted emergency use authorisation (EUA) for coviccine trivalent XBB.1.5-recombinant Covid-19 trivalent (XBB.1.5+BA.5+delta) protein vaccine (Sf9 cell). This marks the world’s first Covid-19 vaccine approved for emergency use against XBB descendent lineages of SARS-CoV-2. The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University.

Vaccines 107

Vaccines 107

pharmaphorum

JUNE 9, 2023

AstraZeneca inks $2bn Treg cell therapy deal with Quell Phil.

106

106

Drug Store News

JUNE 9, 2023

The new product addresses the dynamic vision needs of patients with presbyopia.

105

105

pharmaphorum

JUNE 9, 2023

One size does not fit all: Why a shift is needed in how we treat depression Mike.

105

105

Drug Store News

JUNE 9, 2023

The company kicked off a new webinar series with a focus on pharmacy automation.

105

105

pharmaphorum

JUNE 9, 2023

FDA sets Dec deadline for Vertex, CRISPR sickle cell therapy Phil.

FDA 104

FDA 104

Drug Store News

JUNE 9, 2023

Häagen-Dazs’ Cultured Crème line features yogurts that were inspired by the taste and texture of indulgent ice cream.

104

104

STAT

JUNE 9, 2023

The Food and Drug Administration is convening a meeting of outside experts on Friday to consider full approval for Leqembi, the Alzheimer’s treatment made by Eisai and Biogen. Leqembi was granted conditional approval in January based on preliminary evidence showing it could eliminate toxic brain plaques from people diagnosed with early-stage Alzheimer’s.

FDA 102

FDA 102

Fierce Healthcare

JUNE 9, 2023

Many retail pharmacies do not have buprenorphine in stock, posing a problem for opioid use disorder (OUD) patients, a new study shows. | Pharmacies don’t keep every medication in stock. But that should be the case for buprenorphine, which is time-sensitive for opioid use disorder patients, the study's author argues.

101

101